Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 1062)
Posted On: 08/14/2020 9:41:58 PM
Post# of 154082
Posted By: CTMedic
Re: CTMedic #49706
I am not certain if my reply on NYT was incomplete , is just what I copied to share here.

Just to be safe, I replied once more to mockingjay:

@mockingjay

In a double blinded,
placebo controlled study, Leronlimab demonstrated statistically significant improvement in NEWS2 (National Early Warning Score), a widely accepted UK clinical metric for measuring the progression of COVID into the severe/critical phase. (P=0.02). Leronlimab increased the number of patients who showed clinical improvement in the NEWS2 score, by 150%.

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

https://clinicaltrials.gov/ct2/show/NCT043436...amp;rank=3

The MOA for leronlimab reducing viremia, reversing cytokine storm and restoring immune function has need described by Dr. Bruce Patterson, a virologist formerly at Stanford.

Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277012/

This should be sufficient to demonstrate this is real. You can go to Cytodyn.com, but these other sources are independent.













(12)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site